<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases	</title>
	<atom:link href="https://www.novumpr.nl/2020/01/09/boehringer-ingelheim-partners-with-enleofen-to-develop-first-in-class-anti-il-11-therapies-for-a-range-of-fibrotic-diseases/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2020/01/09/boehringer-ingelheim-partners-with-enleofen-to-develop-first-in-class-anti-il-11-therapies-for-a-range-of-fibrotic-diseases/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=boehringer-ingelheim-partners-with-enleofen-to-develop-first-in-class-anti-il-11-therapies-for-a-range-of-fibrotic-diseases</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Thu, 09 Jan 2020 12:50:54 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
</channel>
</rss>
